Rechallenging nivolumab following immune checkpoint inhibitor-induced pericarditis.
| Autor: | Ali MR; Department of Internal Medicine, King Hussein Cancer Center, Amman, Jordan., Darwish OJ; Department of Internal Medicine, King Hussein Cancer Center, Amman, Jordan., Alhuneafat L; Department of Medicine, Allegheny Health Network, Pittsburgh, Pennsylvania., Abdallah BN; School of Medicine, The University of Jordan, Amman, Jordan., Saleh Y; Department of Internal Medicine, King Hussein Cancer Center, Amman, Jordan. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Proceedings (Baylor University. Medical Center) [Proc (Bayl Univ Med Cent)] 2022 Oct 28; Vol. 36 (1), pp. 83-84. Date of Electronic Publication: 2022 Oct 28 (Print Publication: 2023). |
| DOI: | 10.1080/08998280.2022.2132367 |
| Abstrakt: | We report a case of recurrent pericarditis as an immune-related adverse event in a 47-year-old man with de novo metastatic renal cell carcinoma. After first-line treatment with sunitinib failed, he received three cycles of nivolumab and developed pericarditis following each cycle. The third cycle was accompanied by colchicine as a secondary prophylaxis. Pericarditis is an uncommon and potentially life-threatening immune-related adverse event, if not managed promptly. Competing Interests: The authors report no conflicts of interest. The patient gave permission for his case to be published. (Copyright © 2022 Baylor University Medical Center.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|